Brief: Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation Of Anti-Cancer Immune Cells With Mdna11 In Phase 1/2 Ability Study
02/05/2022 13:55
May 2 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA ANNOUNCES NEW CLINICAL DATA SHOWING
DOSE-DEPENDENT
STIMULATION OF ANTI-CANCER IMMUNE CELLS WITH MDNA11 IN THE PHASE
1/2 ABILITY STUDY
* MEDICENNA - ENROLLING PATIENTS IN TRIAL'S 4TH DOSE
ESCALATION
COHORT AND PROGRESSING TOWARDS EXPECTED INITIAL UPDATE ON
EFFICACY DATA IN MID-2022
* MEDICENNA THERAPEUTICS CORP- MDNA11 CONTINUES TO EXHIBIT
AN
ACCEPTABLE SAFETY PROFILE, NO DOSE LIMITING TOXICITIES REPORTED
IN ABILITY STUDY TO DATE
Source text for Eikon: ID:nGNX1CbGNF
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results